FCRL4 and renal carcinoma: According to The Cancer Genome Atlas (TCGA) data, LUAD tumor progression was accompanied by a decrease in FCRL4 levels, whereas renal carcinoma showed a substantial increase in FCRL4 expression as the tumor progressed from stage I to stage IV.